


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A compound of formula I:



FORMULA I

wherein substituents R1-R7 and X are defined as follows:

R1, R2, R3 and R4 each independently are selected from hydrogen, halogen (selected from F, Cl, Br or I), a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as trifluoromethyl, C<sub>1-6</sub>alkoxy, amino, C<sub>1-6</sub>alkylamino, di(C<sub>1-6</sub>alkylamino), carboxyl, cyano, nitro, formyl, hydroxy, and CO-R, COO-R, CONH-R, and SO<sub>2</sub>-R wherein R is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality.

R5 is one of the following:

- (i) hydrogen, or
- (ii) a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br

or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or

(iii) CO-R8 or COOR8 or CONHR8 or SO<sub>2</sub>R8 wherein R8 may be

a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or

an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen (selected from F, Cl, Br or I), alkyl groups containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as trifluoromethyl, C<sub>1-6</sub>alkyloxy, carboxyl, cyano, nitro, formyl, hydroxy, C<sub>1-6</sub>alkylamino, di(C<sub>1-6</sub>alkyl)amino, and amino, the latter nitrogen substituents optionally in the form of a pendant basic nitrogen functionality; as well as CO-R, COO-R, CONH-R, SO<sub>2</sub>-R, and SO<sub>2</sub>NH-R wherein R is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, CL, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or

a heteroaryl group such as a pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, indolyl, benzimidazole, quinolinyl group, which may additionally bear any combination, at any one ring position, of one or more substituents such as halogen (selected from F, Cl, Br or I), alkyl groups containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as trifluoromethyl, C<sub>1-6</sub>alkyloxy, carboxyl, cyano, nitro, formyl, hydroxy, C<sub>1-6</sub>alkylamino, di(C<sub>1-6</sub>alkyl)amino, and amino, the latter nitrogen substituents

optionally in the form of a pendant basic nitrogen functionality; as well as CO-R, COO-R, CONH-R, SO<sub>2</sub>-R, and SO<sub>2</sub>NH-R wherein R is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality.

R6 and R7 each independently are selected from :

i) hydrogen, a halogen (selected from F, Cl, Br or I), or

ii) an alkyl<sup>1</sup> group defined as a linear, branched or cycloalkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen (the latter optionally in the form of a pendant basic nitrogen functionality); as well as trifluoromethyl, carboxyl, cyano, nitro, formyl ; as well as CO-R, COO-R, CONH-R, SO<sub>2</sub>-R, and SO<sub>2</sub>NH-R wherein R is a linear or branched alkyl group containing 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as a cycloalkyl or aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality, or

(iii) an aryl<sup>1</sup> group defined as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as

halogen (selected from I, F, Cl or Br);

alkyl<sup>1</sup> group;

a cycloalkyl, aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality;

trifluoromethyl, O-alkyl<sup>1</sup> carboxyl, cyano, nitro, formyl, hydroxy, NH- alkyl<sup>1</sup>, N(alkyl<sup>1</sup>)(alkyl<sup>1</sup>), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality;

NHCO-R or NHCOO-R or NHCONH-R or NHSO<sub>2</sub>-R or NHSO<sub>2</sub>NH-R or CO-R or COO-R or CONH-R or SO<sub>2</sub>-R or SO<sub>2</sub>NH-R wherein R corresponds to hydrogen, alkyl<sup>1</sup>, aryl or heteroaryl, or

(iv) a heteroaryl<sup>1</sup> group defined as a pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, indolyl, benzimidazole, quinolinyl group, which may additionally bear any combination, at any one ring position, of one or more substituents such as

halogen (selected from F, Cl, Br or I);

an alkyl<sup>1</sup> group;

a cycloalkyl, aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality,

trifluoromethyl, O-alkyl<sup>1</sup> carboxyl, cyano, nitro, formyl, hydroxy, NH- (alkyl<sup>1</sup>), alkyl<sup>1</sup>, N(alkyl<sup>1</sup>)(alkyl<sup>1</sup>), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality;

NHCO-R or NHCOO-R or NHCONH-R or NHSO<sub>2</sub>-R or NHSO<sub>2</sub>NH-R or CO-R or COO-R or CONH-R or SO<sub>2</sub>-R or SO<sub>2</sub>NH-R wherein R corresponds to hydrogen, alkyl<sup>1</sup>, or

(v) an O-aryl<sup>1</sup>, or NH-aryl<sup>1</sup>, or O-heteroaryl<sup>1</sup> group

(vi) trifluoromethyl, O-alkyl<sup>1</sup>, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl<sup>1</sup>, N(alkyl<sup>1</sup>)(alkyl<sup>1</sup>), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality, or

(vii) NHCO-R or NHCOO-R or NHCONH-R or NHSO<sub>2</sub>-R or NHSO<sub>2</sub>NH-R or CO-R or COO-R or CONH-R or SO<sub>2</sub>-R or SO<sub>2</sub>NH-R wherein R corresponds to hydrogen, alkyl<sup>1</sup>, aryl or heteroaryl.

X is :

-NR<sup>9</sup>R<sup>10</sup>, wherein R<sup>9</sup> and/or R<sup>10</sup> are hydrogen or:

i) an alkyl<sup>1</sup> group, CF<sub>3</sub> or

ii) an aryl<sup>1</sup>, heteroaryl<sup>1</sup> or cycloalkyl group optionally substituted by a pendant basic nitrogen functionality, or

iii) a CO-R, COO-R, CON-RR' or SO<sub>2</sub>-R, where R and R' are a hydrogen, alkyl<sup>1</sup>, aryl<sup>1</sup>, or heteroaryl<sup>1</sup>, optionally substituted by a pendant basic nitrogen functionality;  
or:


-CO-NR<sup>9</sup>R<sup>10</sup>, wherein R<sup>9</sup> and/or R<sup>10</sup> are hydrogen or:

i) an alkyl<sup>1</sup> group, CF<sub>3</sub> or

ii) an aryl<sup>1</sup>, heteroaryl<sup>1</sup>, or cycloalkyl group optionally substituted by a pendant basic nitrogen functionality.


-alkyl<sup>1</sup>.

2. (Original) A compound according to claim 1 of formula I-2 :



wherein R<sup>5</sup> = H, Y and Z represents an hydrogen, an aryl<sup>1</sup> or a heteroaryl<sup>1</sup> group, optionally substituted by a pendant basic nitrogen functionality and wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup>, and R<sup>7</sup> have the meaning as defined in claim 1.


3. (Original) A compound according to claim 1 of formula II:



FORMULA II

Wherein Y is selected-from O, S and Z corresponds to H, NRaRb, alkyl<sup>1</sup>, aryl<sup>1</sup>, O-alkyl<sup>1</sup>, or O-aryl<sup>1</sup>, or wherein Ra and Rb are independently chosen from H or alkyl<sup>1</sup> or aryl<sup>1</sup> or heteroaryl<sup>1</sup>, optionally substituted by a pendant basic nitrogen functionality and wherein R1, R2, R3, R4, R5, R6, and R7 have the meaning as defined in claim 1.


4. (Original) A compound according to claim 3 of formula II-1:



FORMULA II-1

Wherein R5 = H, Y = O or S and Ra, Rb are independently chosen from H or alkyl<sup>1</sup> or aryl<sup>1</sup> or heteroaryl<sup>1</sup>, optionally substituted by a pendant basic nitrogen functionality and wherein R1, R2, R3, R4, R6, and R7 have the meaning as defined in claim 1.

5. (Original) A compound according to claim 4 of formula II-2:




FORMULA II-2

Wherein A is or heteroaryl<sup>1</sup> and

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>6</sub>, R<sub>7</sub>, aryl<sup>1</sup>, heteroaryl<sup>1</sup> have the meaning described on pages as defined in claim 1.


6. (Original) A compound according to claim 4 of formula II-3 :



FORMULA II-3

Wherein R is independently alkyl<sup>1</sup>, aryl<sup>1</sup>, or heteroaryl<sup>1</sup> and wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>7</sub> have the meaning described as defined in claim 1.


7. (Original) A compound according to claim 4 of formula II-4:



FORMULA II-4

Wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>6</sub>, R<sub>7</sub> and alkyl<sup>1</sup> have the meaning as defined in claim 1.


8. (Original) A compound according to claim 1 of formula I-3 :



FORMULA I-3

Wherein R5 = H, X is NHSO<sub>2</sub>R group, R is independently alkyl<sup>1</sup>, aryl<sup>1</sup>, or heteroaryl<sup>1</sup> and wherein , alkyl<sup>1</sup>, aryl<sup>1</sup>, or heteroaryl<sup>1</sup>, R1, R2, R3, R4, R6 and R7 have the meaning as defined in claim 1.


9. (Original) A compound according to claim 1 of formula III:



FORMULA III

Wherein Y is selected from NRaRb, NHNRaRb, alkyl<sup>1</sup>, aryl<sup>1</sup>, Ra wherein Ra and Rb are independently chosen from H or alkyl<sup>1</sup> or aryl<sup>1</sup> or heteroaryl<sup>1</sup>, optionally substituted by a pendant basic nitrogen functionality and wherein R1, R2, R3, R4, R6, and R7 have the meaning as defined in claim 1.

10. (Original) A compound according to claim 1 of formula IV:



FORMULA IV



Wherein alkyl<sup>1</sup>, R1, R2, R3, R4, R6, and R7 have the meaning as defined in claim 1.

11. (Original) A compound as claimed in claim 1 selected from :

4- {[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoic acid methyl ester;

4-Methyl-M- (5-pyridin-3-yl-oxazol-2-yl)-N3- (5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine ;

4-Methyl-N1- (5-phenyl-oxazol-2-yl)-N3- (5-pyridin-4-yl-oxazol-2-yl)-benzene-1, 3-diamine;

4-Methyl-M- (5-phenyl- [ 1, 3,4] oxadiazol-2-yl)-N3- (5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine ;

N1-Benzooxazol-2-yl-4-methyl-N3-(5-pyridin-4-yl-oxazol-2-yl)-benzene-1, 3-diamine ;

N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide ;

2-Cyano-N- [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide ;

2-Ethoxy-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide ;

3-Methoxy-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-propionamide ;

1- [4-Methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-p-tolyl-urea ;

1-(4-Cyano-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea ;

1-(4-Fluoro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea ;

1-(2-Fluoro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea ;

1-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-(4-trifluoromethyl-phenyl) -urea;

1-(4-Chloro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea ;

1- [4-Methyl-3- (5-phenyl-oxazol-2-ylamino)-phenyl]-3- (3-trifluoromethyl-phenyl)-  
urea;

1-(4-Cyano-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-  
thiourea;

1- (4-Cyano-phenyl)-3- [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-  
thiourea;

(2- {2-Methyl-5- [3- (4-trifluoromethyl-phenyl)-ureido]-phenylamino}-oxazol-5-yl)-  
acetic acid ethyl ester;

1-Benzyl-3-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-thiourea ;

4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-  
phenyl]-benzamide ;

3-Dimethylamino-N- [4-methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]- benzamide ;

3-Bromo-N- [4-methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-benzamide ;

N-[4-Methoxy-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-  
benzamide;

4- (3-Dimethylamino-propylamino)-N [4-methyl-3- (5-pyridin-3-yl-oxazol-2-  
ylamino)-phenyl]-3-trifluoromethyl-benzamide ;

N-[4-Fluoro-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-  
benzamide;

1H-indole-6-carboxylic acid [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-  
amide;

3-Isopropoxy-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide ;

N-[4-Methyl-3-(5-pyridin-2-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;

3, 5-Dimethoxy-N [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide;

N-[3-(5-Pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide ;

N- [4-Methyl-3- (5-phenyl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide ;

3-Fluoro-4- (4-methyl-piperazin-1-ylmethyl)-N- [4-methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino) -phenyl] -benzamide ;

N-[4-Chloro-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;

N- [4-Methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-terephthalamide ;

5-Methyl-isoxazole-4-carboxylic acid [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-amide ;

4-Cyano-N [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide ;

N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-isonicotinamide ;

N- [4-Methyl-3- (4-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;

[4-Methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-carbamic acid isobutyl ester;

(5-Isobutoxycarbonylamino-2-methyl-phenyl)- (5-pyridin-3-yl-oxazol-2-yl)-carbamic acid isobutyl ester;

[4-Methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-carbamic acid isobutyl ester;

N-[4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-2-m-tolyl-acetamide ;

2-(4-Fluoro-phenyl)-N-[4-methoxy-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;

2-(2,4-Difluoro-phenyl)-N-[4-methyl-3-(5-phenyl-oxazol-2-ylamino)-phenyl]-acetamide;

2-(3-Bromo-phenyl)-N-[4-methyl-3-(5-pyridin-2-yl-oxazol-2-ylamino)-phenyl]-acetamide;

3-(4-Fluoro-phenyl)-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-propionamide;

2-(4-Fluoro-phenyl)-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide;

N-{3-[5-(4-Cyano-phenyl)-oxazol-2-ylamino]-4-methyl-phenyl}-2-(2,4-difluoro-phenyl)-acetamide;

4-Methyl-pentanoic acid [4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-amide;

N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-2-piperazin-1-yl-acetamide;

N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-piperazin-1-yl-propionamide;

2-(2,6-Dichloro-phenyl)-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide ;

N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-pyrrolidin-1-yl-propionamide;

N-[4-Methoxy-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-2-(4-trifluoromethyl-phenyl)-acetamide ;

2-(4-Methoxy-phenyl)-N- [4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;

N- [4-Methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-C-phenyl-methanesulfonamide ;

N-(4-Cyano-phenyl)-4-methyl-3- (5-pyridin-3-yl-oxazol-2-ylamino)-benzamide ;

N- (3-Dimethylamino-phenyl)-4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;

N-(2-Dimethylamino-ethyl)-4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-benzamide;

N- (3-Fluoro-4-methyl-phenyl)-4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;

N-(3-Chloro-phenyl)-4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-benzamide ;

N-Benzyl-4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-benzamide ;

N-(4-Methoxy-benzyl)-4-methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-benzamide ;

[4-Methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-morpholin-4-yl-methanone ;

[4-Methyl-3- (5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-piperazin-1-yl-methanone ;

N-(4-Fluoro-phenyl)-2-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide

12. (Currently Amended) A compound according to claim 1, ~~one of claims 1 to 10~~, wherein R6 is hydrogen and R7 is pyridyl, which may additionally bear any combination, at any one ring position, of one or more substituents such as

- halogen (selected from F, Cl, Br or I) ;
- an alkyl<sup>1</sup> group;

- an aryl<sup>1</sup> group;
- trifluoromethyl, O-alkyl<sup>1</sup>, carboxyl, cyano, nitro, formyl, hydroxy, NH- alkyl<sup>1</sup>, N (alkyl<sup>1</sup>) (alkyl<sup>1</sup>), and amino, the latter nitrogen substituents optionally in the of a basic nitrogen functionality; or
- NHCOO-R or NHCONH-R or NHSO<sub>2</sub>-R or NHSO<sub>2</sub>NH-R or CO-R or COO-R or CONH-R or SO<sub>2</sub>-R or SO<sub>2</sub>NH-R wherein R corresponds to hydrogen, alkyl or group.

13. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 1. ~~one of claims 1 to 12.~~

14. (Currently Amended) A pharmaceutical composition according to claim 13 further comprising a pharmaceutically acceptable carrier.

15. (Currently Amended) A pharmaceutical composition according to claim 14 formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, and suspensions.

16. (Currently Amended) A cosmetic or pharmaceutical composition for topical administration comprising a compound according to claim 1. ~~one of claims 1 to 12.~~

17-22. (Canceled)